ipilimumab
bms
['melsm', 'melanoma', 'ipilimumab']
a randomized phase 3 trial presented at 2022 esmo revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage iiic/iv unresectable, treatment-refractory melanoma. #melsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.